NIPT, or Non-Invasive Prenatal Testing, involves analyzing fetal DNA from a pregnant woman's blood sample to assess the risk of genetic abnormalities in the developing fetus. This method screens for chromosomal abnormalities, particularly trisomies associated with Down syndrome, Edwards syndrome, and Patau syndrome, by examining small circulating DNA fragments in the maternal bloodstream.
The NIPT market is poised for future growth, driven by a confluence of micro and macro trends such as increased awareness for early chromosomal abnormality detection and prevention, the rise in adoption of non-invasive methods, and the consumerization of diagnostic tests. Anticipated technological leaps include offerings beyond chromosomal abnormalities, moving from research to clinical testing, early pregnancy testing enabling faster intervention, and increased affordability due to technological advancements and wider insurance coverage.
Recently, BIS Research recently released the Non-Invasive Prenatal Testing (NIPT) Market report which covers the period from 2023 to 2033, with a base year of 2022. The market size reached $3.35 billion in 2023 and is projected to grow to $12.87 billion by 2033, with a CAGR of 14.41% during the forecast period. The report spans 180 pages and includes 110 tables and 68 figures.
Drivers
• High incidence of genetic disorders
• Rising maternal age
• Increasing number of reimbursement policies toward genetics coverage
Challenges
• Stringent regulatory guidelines and ethical hurdles
• Lack of awareness regarding NIPT
• Limitations of NIPT
Opportunities
• Leveraging the opportunities arising from the growing markets in Asia
• Increasing focus on non-invasive pre-implantation genetic testing (niPGT)
Click Here to Download Free Sample
Segmentation 1: by Application
• Trisomy Detection
• Microdeletion Detection
• Sex Chromosome Aneuploidy Detection
• Others
Segmentation 2: by End User
• Hospitals
• Diagnostic Laboratories
• Others
Segmentation 4: by Method
• cfDNA
• FCMB
Segmentation 5: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
Overview: The global Non-Invasive Prenatal Testing (NIPT) market, segmented by application, end user, platform, method, and region, shows significant trends. Trisomy detection leads the market due to its high specificity and increased demand driven by rising chromosomal abnormalities and maternal age. Hospitals dominate as end users, leveraging existing maternity services and genetic counseling access. Next-Generation Sequencing (NGS) platforms dominate, offering affordability and integration with other technologies. Cell-free DNA (cfDNA) methods dominate, with applications in fetal sex determination and single-gene disorder identification. Asia-Pacific exhibits notable growth, driven by increasing market players and evolving healthcare landscapes.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• PerkinElmer, Inc.
• Quest Diagnostics Incorporated
• Illumina, Inc.
• Myriad Genetics, Inc.
• BGI Genomics
• CENTOGENE N.V.
• Laboratory Corporation of America Holdings
• MedGenome Inc.
• Annoroad Gene Technology
• Natera, Inc.
• Yourgene Health
• Eurofins Scientific SE
• Next Biosciences
Swati Sood, BIS Principal Analyst, “Key trends in the NIPT market include growing strategic partnerships and alliances among market players to drive innovation, expand market presence, and ensure regulatory compliance. Additionally, there's a notable trend of expanding applications in NIPT products, with increased investment in research and development to detect additional genetic conditions, microdeletions, and single-gene disorders, enhancing clinical utility and positioning NIPT as a versatile tool for prenatal genetic screening.”
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn more.
